Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 16:23, 16 April 2024

5,736 bytes added ,  16:23, 16 April 2024
Updated
Line 1: Line 1:  
Welcome!
 
Welcome!
 +
 +
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
    
*For assignments, please see the "Author" column below (highlighted blue).
 
*For assignments, please see the "Author" column below (highlighted blue).
−
**If empty (no name is present), please volunteer to create content for that disease!
+
 
−
**If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
+
*If empty (no name is present), please volunteer to create content for that disease!
 +
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 +
 
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
−
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added.
+
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
    
<br />
 
<br />
 
{| class="wikitable" style="margin:auto"
 
{| class="wikitable" style="margin:auto"
−
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content</big>
+
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
 
|-
 
|-
 
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
 
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
−
!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
+
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
Line 49: Line 53:  
----<br />
 
----<br />
 
|-
 
|-
−
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
+
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
 +
|4/8/24
 +
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 782: Line 788:  
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 798: Line 804:  
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 1,274: Line 1,280:  
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
 
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
 
|Disease
 
|Disease
−
|Holli Drendel authoring - Complete? Looks like needs more editing of tables
+
|Holli Drendel
−
|
   
|
 
|
 
|
 
|
 +
|?Complete? Looks like tables need more editing.
 
|
 
|
 
|HD
 
|HD
Line 1,467: Line 1,473:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
 
| || || || ||Shivani Golem (SG)
 
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 
|Monoclonal B-cell Lymphocytosis
 
|Monoclonal B-cell Lymphocytosis
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
−
|PENDING
+
|PENDING, 4/30/2024
 
|
 
|
 
|Assigned 12/19/2022 with completion date of 1/19/2023
 
|Assigned 12/19/2022 with completion date of 1/19/2023
Line 1,481: Line 1,487:     
Honey Reddi, PhD, Belay Diagnostics
 
Honey Reddi, PhD, Belay Diagnostics
−
| || ||Complete (Shivani, please confirm)|| ||SG|| ||
+
| || ||Complete|| ||SG|| ||
 
|Already converted to 5th edition
 
|Already converted to 5th edition
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
Line 1,488: Line 1,494:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Hairy Cell Leukemia
 
|Hairy Cell Leukemia
Line 1,496: Line 1,502:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Marginal Zone Lymphoma
 
|Splenic Marginal Zone Lymphoma
Line 1,504: Line 1,510:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
Line 1,514: Line 1,520:  
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|Disease
 
|Disease
−
|PENDING
+
|
 
|
 
|
 
|
 
|
Line 1,808: Line 1,814:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
 +
|3/22/24|| ||Pending|| ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,890: Line 1,897:  
|
 
|
 
|-
 
|-
−
|Burkitt lymphoma||Disease||PENDING
+
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
 
| || || || ||GC|| ||
 
| || || || ||GC|| ||
 
|Burkitt Lymphoma
 
|Burkitt Lymphoma
Line 1,898: Line 1,905:  
|
 
|
 
|-
 
|-
−
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,905: Line 1,912:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,912: Line 1,919:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,919: Line 1,926:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| ||
+
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,926: Line 1,933:  
|
 
|
 
|-
 
|-
−
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
+
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
 
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
 
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
 
| || || || ||GC|| ||
 
| || || || ||GC|| ||
Line 1,935: Line 1,942:  
|
 
|
 
|-
 
|-
−
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,942: Line 1,949:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
+
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,949: Line 1,956:  
|
 
|
 
|-
 
|-
−
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| ||
+
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,956: Line 1,963:  
|
 
|
 
|-
 
|-
−
|Classic Hodgkin lymphoma||Disease||PENDING
+
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
−
| || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
+
| || || ||
−
|GC|| ||
+
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
 
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
 
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
 
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
 
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
Line 1,965: Line 1,972:  
|
 
|
 
|-
 
|-
−
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,972: Line 1,979:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Cold agglutinin disease
+
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,988: Line 1,995:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,995: Line 2,002:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,002: Line 2,009:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
+
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,010: Line 2,017:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Immunoglobulin-related (AL) amyloidosis||Disease||PENDING
+
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
 
| || || || ||SG
 
| || || || ||SG
 
| ||
 
| ||
Line 2,019: Line 2,026:  
|
 
|
 
|-
 
|-
−
|Monoclonal immunoglobulin deposition disease||Disease||PENDING
+
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
 
| || || || ||SG
 
| || || || ||SG
 
| ||
 
| ||
Line 2,028: Line 2,035:  
|
 
|
 
|-
 
|-
−
|Mu heavy chain disease||Disease|| || || || || ||SG
+
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,036: Line 2,043:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Gamma heavy chain disease||Disease||PENDING
+
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
 
| || || || ||SG
 
| || || || ||SG
 
| ||
 
| ||
Line 2,045: Line 2,052:  
|
 
|
 
|-
 
|-
−
|Alpha heavy chain disease||Disease|| || || || || ||SG
+
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,053: Line 2,060:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Plasmacytoma||Disease||PENDING
+
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
−
| || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
+
| || || ||
 
|SG
 
|SG
−
| ||
+
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
 
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
 
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,063: Line 2,070:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Plasma cell myeloma / multiple myeloma||Disease||PENDING
+
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
−
| || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG
+
| || || || ||SG
−
| ||
+
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
 
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
 
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
 
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
 
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
Line 2,072: Line 2,079:  
|
 
|
 
|-
 
|-
−
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||PENDING
+
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
−
| || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
+
| || || ||
 
|SG
 
|SG
−
| ||
+
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
 
|(1) POEMS Syndrome + (2) TEMPI Syndrome
 
|(1) POEMS Syndrome + (2) TEMPI Syndrome
 
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
 
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
Line 2,081: Line 2,088:  
|
 
|
 
|
 
|
 +
|-
 +
|Disease (5th Edition)
 +
|Page Type
 +
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
 +
|Date Assigned to Author (5th Edition)
 +
|Target Completion Date (5th Edition)
 +
|Content Status (5th Edition) (Pending or Complete)
 +
|Date Completed by Author (5th Edition)
 +
|Associate Editor
 +
|Date of Last Editor Review (5th Edition)
 +
|Notes (5th Edition)
 +
|Correlated Prior Disease Name (4th Edition)
 +
|Correlated Prior Author (4th Edition)
 +
|Prior Content Status (4th Edition) (Pending or Complete)
 +
|Prior Date of Last Editor Review (4th Edition)
 +
|Prior Notes (4th Edition)
 
|-
 
|-
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Line 2,112: Line 2,135:  
----<br />
 
----<br />
 
|-
 
|-
−
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
+
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,120: Line 2,143:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,127: Line 2,152:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,134: Line 2,159:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
+
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,141: Line 2,166:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Early T-precursor lymphoblastic leukaemia / lymphoma
+
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 
|Disease
 
|Disease
−
|PENDING
+
|Fei Yang, MD
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
−
|
+
|SK
−
|HD
   
|
 
|
 
|
 
|
Line 2,157: Line 2,182:  
|
 
|
 
|-
 
|-
−
|T-prolymphocytic leukaemia
+
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|Disease
 
|Disease
 +
|Parastou Tizro, MD (trainee);
 +
Sumire Kitahara, MD
 +
|3/17/2024
 
|
 
|
−
|
+
|Pending
−
|
  −
|
   
|
 
|
 
|SK
 
|SK
Line 2,173: Line 2,199:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|T-large granular lymphocytic leukaemia||Disease||PENDING
+
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
−
| || || || ||SK|| ||
+
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|T-cell Large Granular Lymphocytic Leukemia
 
|T-cell Large Granular Lymphocytic Leukemia
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,181: Line 2,210:  
|
 
|
 
|-
 
|-
−
|NK-large granular lymphocytic leukaemia||Disease||PENDING
+
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
−
| || || || ||SK|| ||
+
Michelle Don, MD, MS
 +
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Michelle Don, MD
 
|Michelle Don, MD
Line 2,189: Line 2,222:  
|
 
|
 
|-
 
|-
−
|Adult T-cell leukaemia/lymphoma||Disease||PENDING
+
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Adult T-cell Leukemia/Lymphoma
 
|Adult T-cell Leukemia/Lymphoma
Line 2,197: Line 2,230:  
|
 
|
 
|-
 
|-
−
|Sezary syndrome||Disease||PENDING
+
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Sézary Syndrome
 
|Sézary Syndrome
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,205: Line 2,239:  
|
 
|
 
|-
 
|-
−
|Aggressive NK-cell leukaemia||Disease||PENDING
+
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Aggressive NK-cell Leukemia
 
|Aggressive NK-cell Leukemia
Line 2,213: Line 2,247:  
|
 
|
 
|-
 
|-
−
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,220: Line 2,257:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,227: Line 2,269:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Mycosis fungoides||Disease||PENDING
+
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Mycosis Fungoides
 
|Mycosis Fungoides
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,235: Line 2,278:  
|
 
|
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,242: Line 2,285:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||PENDING
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Primary Cutaneous Anaplastic Large Cell Lymphoma
 
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,250: Line 2,293:  
|
 
|
 
|-
 
|-
−
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,257: Line 2,303:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
 +
| || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,264: Line 2,311:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024|| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,271: Line 2,322:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,278: Line 2,329:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||PENDING
+
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Line 2,286: Line 2,337:  
|
 
|
 
|-
 
|-
−
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,293: Line 2,344:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Enteropathy-associated T-cell lymphoma||Disease||PENDING
+
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| || || || ||SK|| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 
|Enteropathy-Associated T-cell Lymphoma
 
|Enteropathy-Associated T-cell Lymphoma
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
Line 2,301: Line 2,354:  
|
 
|
 
|-
 
|-
−
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||PENDING
+
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| || || || ||SK|| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Line 2,309: Line 2,364:  
|
 
|
 
|-
 
|-
−
|Intestinal T-cell lymphoma, NOS||Disease||PENDING
+
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
Line 2,317: Line 2,372:  
|
 
|
 
|-
 
|-
−
|Hepatosplenic T-cell lymphoma||Disease||PENDING
+
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
−
| || || || ||SK|| ||
+
Michelle Don, MD, MS
 +
|3/19/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|Hepatosplenic T-cell Lymphoma
 
|Hepatosplenic T-cell Lymphoma
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,325: Line 2,384:  
|
 
|
 
|-
 
|-
−
|ALK-positive anaplastic large cell lymphoma||Disease||PENDING
+
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| || || || ||SK|| ||
+
 
 +
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Miguel Gonzalez Mancera, MD
 
|Miguel Gonzalez Mancera, MD
Line 2,337: Line 2,399:  
|
 
|
 
|-
 
|-
−
|ALK-negative anaplastic large cell lymphoma||Disease||PENDING
+
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| || || || ||SK|| ||
+
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
Line 2,345: Line 2,409:  
|
 
|
 
|-
 
|-
−
|Breast implant-associated anaplastic large cell lymphoma||Disease||PENDING
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
−
| || || || ||SK|| ||
+
|4/1/2024
 +
| ||Pending|| ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Line 2,353: Line 2,418:  
|
 
|
 
|-
 
|-
−
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
−
| ||Pending|| ||SK|| ||
+
| ||Pending|| ||SK|| ||prior authors not available
 
|Angioimmunoblastic T-cell Lymphoma
 
|Angioimmunoblastic T-cell Lymphoma
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,361: Line 2,426:  
|
 
|
 
|-
 
|-
−
|Nodal TFH cell lymphoma, follicular-type||Disease||Rachel Burnside||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
 
| ||Pending|| ||SK|| ||
 
| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,369: Line 2,434:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Nodal TFH cell lymphoma, NOS||Disease||PENDING
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
Line 2,377: Line 2,442:  
|
 
|
 
|-
 
|-
−
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
 +
|6/25/2023
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,384: Line 2,451:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,391: Line 2,458:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,398: Line 2,468:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,405: Line 2,475:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,412: Line 2,482:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,419: Line 2,491:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||PENDING
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
−
| || || || ||SK|| ||
+
|3/25/2024
 +
| || || ||SK|| ||prior authors not available
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Line 2,457: Line 2,530:  
----<br />
 
----<br />
 
|-
 
|-
−
|Follicular dendritic cell sarcoma
+
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
 
|Disease
 
|Disease
 
|PENDING
 
|PENDING
Line 2,473: Line 2,546:  
|
 
|
 
|-
 
|-
−
|EBV-positive inflammatory follicular dendritic cell sarcoma
+
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,489: Line 2,562:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Fibroblastic reticular cell tumour
+
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,505: Line 2,578:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Intranodal palisaded myofibroblastoma
+
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,521: Line 2,594:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Littoral cell angioma
+
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,537: Line 2,610:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Splenic hamartoma
+
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,553: Line 2,626:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
+
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
 
|Disease
 
|Disease
 
|
 
|
Line 2,599: Line 2,672:  
----<br />
 
----<br />
 
|-
 
|-
−
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
+
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,606: Line 2,679:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Bloom syndrome||Disease|| || || || || ||NA|| ||
+
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,613: Line 2,686:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
+
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,620: Line 2,693:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|RASopathies||Disease|| || || || || ||NA|| ||
+
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/14011...14409"